表 2.
Adverse events | Patients(n=762) | SILD IV-CYC (n=506) | HD IV-CYC (n=256) | P values | |||||
n | % | n | % | n | % | ||||
Data were presented as count (percentage). * P < 0.05. a, a total of 423 female patients aged between 16 and 45 were included in 762 patients with SLE; b, a total of 282 female patients with age between 16 and 45 were included in SILD IV-CYC group; c, a total of 141 female patients with age between 16 and 45 were included in HD IV-CYC group. SILD IV-CYC, short-interval low-dose intravenous cyclophosphamide; HD IV-CYC, high-dose intravenous cyclophosphamide; SLE, systemic lupus erythematosus. | |||||||||
Infection | 123 | 16.14 | 66 | 13.04 | 57 | 22.27 | 0.001* | ||
Gastrointestinal reaction | 168 | 22.05 | 88 | 17.39 | 80 | 31.25 | < 0.001* | ||
Myelosuppression | 100 | 13.12 | 49 | 9.68 | 51 | 19.92 | < 0.001* | ||
Abnormal menstruation | 127a | 30.02 | 71b | 25.18 | 56c | 39.72 | 0.001* | ||
Drug-induced hepatic injury | 46 | 6.04 | 27 | 5.34 | 19 | 7.42 | 0.253 | ||
Hemorrhagic cystitis | 4 | 0.52 | 3 | 0.59 | 1 | 0.39 | 1.000 | ||
Fatigue | 46 | 6.04 | 33 | 6.52 | 13 | 5.08 | 0.429 | ||
Alopecia | 117 | 15.35 | 68 | 13.44 | 49 | 19.14 | 0.039* | ||
Rash | 12 | 1.57 | 10 | 1.98 | 2 | 0.78 | 0.355 |